These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 30852368)

  • 1. Mechanisms of MTH1 inhibition-induced DNA strand breaks: The slippery slope from the oxidized nucleotide pool to genotoxic damage.
    Rai P; Sobol RW
    DNA Repair (Amst); 2019 May; 77():18-26. PubMed ID: 30852368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: more bad news than good?
    Abbas HHK; Alhamoudi KMH; Evans MD; Jones GDD; Foster SS
    BMC Cancer; 2018 Apr; 18(1):423. PubMed ID: 29661172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OGG1 co-inhibition antagonizes the tumor-inhibitory effects of targeting MTH1.
    Zhang L; Misiara L; Samaranayake GJ; Sharma N; Nguyen DM; Tahara YK; Kool ET; Rai P
    Redox Biol; 2021 Apr; 40():101848. PubMed ID: 33450725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool.
    Gad H; Koolmeister T; Jemth AS; Eshtad S; Jacques SA; Ström CE; Svensson LM; Schultz N; Lundbäck T; Einarsdottir BO; Saleh A; Göktürk C; Baranczewski P; Svensson R; Berntsson RP; Gustafsson R; Strömberg K; Sanjiv K; Jacques-Cordonnier MC; Desroses M; Gustavsson AL; Olofsson R; Johansson F; Homan EJ; Loseva O; Bräutigam L; Johansson L; Höglund A; Hagenkort A; Pham T; Altun M; Gaugaz FZ; Vikingsson S; Evers B; Henriksson M; Vallin KS; Wallner OA; Hammarström LG; Wiita E; Almlöf I; Kalderén C; Axelsson H; Djureinovic T; Puigvert JC; Häggblad M; Jeppsson F; Martens U; Lundin C; Lundgren B; Granelli I; Jensen AJ; Artursson P; Nilsson JA; Stenmark P; Scobie M; Berglund UW; Helleday T
    Nature; 2014 Apr; 508(7495):215-21. PubMed ID: 24695224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased MTH1-specific 8-oxodGTPase activity is a hallmark of cancer in colon, lung and pancreatic tissue.
    McPherson LA; Troccoli CI; Ji D; Bowles AE; Gardiner ML; Mohsen MG; Nagathihalli NS; Nguyen DM; Robbins DJ; Merchant NB; Kool ET; Rai P; Ford JM
    DNA Repair (Amst); 2019 Nov; 83():102644. PubMed ID: 31311767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed cell death triggered by nucleotide pool damage and its prevention by MutT homolog-1 (MTH1) with oxidized purine nucleoside triphosphatase.
    Nakabeppu Y; Oka S; Sheng Z; Tsuchimoto D; Sakumi K
    Mutat Res; 2010 Nov; 703(1):51-8. PubMed ID: 20542142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy.
    Huber KV; Salah E; Radic B; Gridling M; Elkins JM; Stukalov A; Jemth AS; Göktürk C; Sanjiv K; Strömberg K; Pham T; Berglund UW; Colinge J; Bennett KL; Loizou JI; Helleday T; Knapp S; Superti-Furga G
    Nature; 2014 Apr; 508(7495):222-7. PubMed ID: 24695225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MutT Homolog 1 (MTH1): The Silencing of a Target.
    Papeo G
    J Med Chem; 2016 Mar; 59(6):2343-5. PubMed ID: 26924380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Existence of MTH1-independent 8-oxodGTPase Activity in Cancer Cells as a Compensatory Mechanism against On-target Effects of MTH1 Inhibitors.
    Samaranayake GJ; Troccoli CI; Zhang L; Huynh M; Jayaraj CJ; Ji D; McPherson L; Onishi Y; Nguyen DM; Robbins DJ; Karbaschi M; Cooke MS; Barrientos A; Kool ET; Rai P
    Mol Cancer Ther; 2020 Feb; 19(2):432-446. PubMed ID: 31744893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MutT homologue 1 (MTH1) catalyzes the hydrolysis of mutagenic O6-methyl-dGTP.
    Jemth AS; Gustafsson R; Bräutigam L; Henriksson L; Vallin KSA; Sarno A; Almlöf I; Homan E; Rasti A; Warpman Berglund U; Stenmark P; Helleday T
    Nucleic Acids Res; 2018 Nov; 46(20):10888-10904. PubMed ID: 30304478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation and development of MTH1 inhibitors for treatment of cancer.
    Warpman Berglund U; Sanjiv K; Gad H; Kalderén C; Koolmeister T; Pham T; Gokturk C; Jafari R; Maddalo G; Seashore-Ludlow B; Chernobrovkin A; Manoilov A; Pateras IS; Rasti A; Jemth AS; Almlöf I; Loseva O; Visnes T; Einarsdottir BO; Gaugaz FZ; Saleh A; Platzack B; Wallner OA; Vallin KS; Henriksson M; Wakchaure P; Borhade S; Herr P; Kallberg Y; Baranczewski P; Homan EJ; Wiita E; Nagpal V; Meijer T; Schipper N; Rudd SG; Bräutigam L; Lindqvist A; Filppula A; Lee TC; Artursson P; Nilsson JA; Gorgoulis VG; Lehtiö J; Zubarev RA; Scobie M; Helleday T
    Ann Oncol; 2016 Dec; 27(12):2275-2283. PubMed ID: 27827301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxic Signaling and the Cellular Redox Tumor Environment Determine Sensitivity to MTH1 Inhibition.
    Bräutigam L; Pudelko L; Jemth AS; Gad H; Narwal M; Gustafsson R; Karsten S; Carreras Puigvert J; Homan E; Berndt C; Berglund UW; Stenmark P; Helleday T
    Cancer Res; 2016 Apr; 76(8):2366-75. PubMed ID: 26862114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The roles of human MTH1, MTH2 and MTH3 proteins in maintaining genome stability under oxidative stress.
    Hashiguchi K; Hayashi M; Sekiguchi M; Umezu K
    Mutat Res; 2018 Mar; 808():10-19. PubMed ID: 29482072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MutT homologue 1 (MTH1) removes N6-methyl-dATP from the dNTP pool.
    Scaletti ER; Vallin KS; Bräutigam L; Sarno A; Warpman Berglund U; Helleday T; Stenmark P; Jemth AS
    J Biol Chem; 2020 Apr; 295(15):4761-4772. PubMed ID: 32144205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of micronucleus induction in MTH1 knockdown cells exposed to UVA, UVB or UVC.
    Fotouhi A; Cornella N; Ramezani M; Wojcik A; Haghdoost S
    Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():161-5. PubMed ID: 26520386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MTH1 inhibition synergizes with ROS-inducing agents to trigger cervical cancer cells undergoing parthanatos.
    Li C; Xue Y; Wu J; Zhang L; Yang T; Ai M; Han J; Zheng X; Wang R; Boldogh I; Ba X
    Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167190. PubMed ID: 38657912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitor development of MTH1 via high-throughput screening with fragment based library and MTH1 substrate binding cavity.
    Peng C; Li YH; Yu CW; Cheng ZH; Liu JR; Hsu JL; Hsin LW; Huang CT; Juan HF; Chern JW; Cheng YS
    Bioorg Chem; 2021 May; 110():104813. PubMed ID: 33774493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MTH1 as a Chemotherapeutic Target: The Elephant in the Room.
    Samaranayake GJ; Huynh M; Rai P
    Cancers (Basel); 2017 May; 9(5):. PubMed ID: 28481306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure of human MTH1, a Nudix family hydrolase that selectively degrades oxidized purine nucleoside triphosphates.
    Mishima M; Sakai Y; Itoh N; Kamiya H; Furuichi M; Takahashi M; Yamagata Y; Iwai S; Nakabeppu Y; Shirakawa M
    J Biol Chem; 2004 Aug; 279(32):33806-15. PubMed ID: 15133035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Double-Edged Sword: The Anti-Cancer Effects of Emodin by Inhibiting the Redox-Protective Protein MTH1 and Augmenting ROS in NSCLC.
    Wahi D; Soni D; Grover A
    J Cancer; 2021; 12(3):652-681. PubMed ID: 33403025
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.